Elanco Animal Health Again Cuts Annual Guidance After Mixed Q2 Earnings
Elanco Animal Health Inc (NYSE: ELAN) has reported a Q2 adjusted EPS of $0.36, higher than the $0.28 reported a year ago, surpassing analysts' view of $0.25.
Revenue was $1.177 billion, a decrease of 8% Y/Y on a reported basis, or down 4%, excluding the unfavorable impact of foreign exchange rates, almost in line with the consensus of $1.18 billion.
Pet Health's revenue decreased by 11% (-7% CER) to $612 million, with a 1% increase in price partially offset by rebate and in-store marketing programs, primarily in the U.S. retail business.
Farm Animal revenue decreased 2% (+3% CER) as Rumensin sales were partially offset by pressured economics for swine and poultry producers in China and a decline for swine in Europe.
Adjusted gross margin improved by 190 bps compared to 58.9%.
Guidance: Elanco expects FY22 revenue of $4.46 - $4.55 billion, down from previous guidance of $4.70 - $4.76 billion and the consensus of $4.69 billion.
It expects adjusted EPS of $1.06-$1.13, down from previous guidance of $1.15 - $1.21 (consensus of $1.14).
The company lowered adjusted EBITDA guidance to $1.06-$1.1 billion vs. the previous outlook of $1.12 - $1.16 billion.
For Q3, the company forecasts revenue of $1.01-$1.06 billion, below the consensus of $1.14 billion.
It expects adjusted EPS of $0.12 - $0.18 (consensus of $0.26) and adjusted EBITDA of $175 million - $215 million.
Price Action: ELAN shares are up 3.60% at $20.14 during the premarket session on the last check Monday.
See more from Benzinga
Kodiak's Eye Disease Candidate At Par With Regeneron's Eylea In Visual Acuity Gains
Karuna Therapeutics Shares Surge After Encouraging Data From Schizophrenia Candidate
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.